Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 86

1.

Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.

Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD.

Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944.

2.

IRAK-M alters the polarity of macrophages to facilitate the survival of Mycobacterium tuberculosis.

Shen P, Li Q, Ma J, Tian M, Hong F, Zhai X, Li J, Huang H, Shi C.

BMC Microbiol. 2017 Aug 23;17(1):185. doi: 10.1186/s12866-017-1095-2.

3.

Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context.

Kapp K, Schneider J, Schneider L, Gollinge N, Jänsch S, Schroff M, Wittig B, Kleuss C.

Immun Inflamm Dis. 2016 Oct 18;4(4):446-462. eCollection 2016 Dec.

4.

Human effector B lymphocytes express ARID3a and secrete interferon alpha.

Ward JM, Ratliff ML, Dozmorov MG, Wiley G, Guthridge JM, Gaffney PM, James JA, Webb CF.

J Autoimmun. 2016 Dec;75:130-140. doi: 10.1016/j.jaut.2016.08.003. Epub 2016 Aug 10.

5.

Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.

Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M, Fritschi U, Vlamopoulos Y, Burruni R, Legris AS, Dartiguenave F, Gharbi D, Martin V, Vaucher L, Speiser DE, Romero P, Jichlinski P, Nardelli-Haefliger D.

Clin Cancer Res. 2017 Feb 1;23(3):717-725. doi: 10.1158/1078-0432.CCR-16-1189. Epub 2016 Aug 12.

6.

Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.

Hopkins RJ, Kalsi G, Montalvo-Lugo VM, Sharma M, Wu Y, Muse DD, Sheldon EA, Hampel FC, Lemiale L.

Vaccine. 2016 Apr 19;34(18):2096-105. doi: 10.1016/j.vaccine.2016.03.006. Epub 2016 Mar 12.

7.

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.

Nakamura R, La Rosa C, Longmate J, Drake J, Slape C, Zhou Q, Lampa MG, O'Donnell M, Cai JL, Farol L, Salhotra A, Snyder DS, Aldoss I, Forman SJ, Miller JS, Zaia JA, Diamond DJ.

Lancet Haematol. 2016 Feb;3(2):e87-98. doi: 10.1016/S2352-3026(15)00246-X. Epub 2015 Dec 24.

8.

Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

Cross AS, Greenberg N, Billington M, Zhang L, DeFilippi C, May RC, Bajwa KK.

Vaccine. 2015 Nov 27;33(48):6719-26. doi: 10.1016/j.vaccine.2015.10.072. Epub 2015 Oct 26.

9.

CpG-DNA enhances the tight junction integrity of the bronchial epithelial cell barrier.

Kubo T, Wawrzyniak P, Morita H, Sugita K, Wanke K, Kast JI, Altunbulakli C, Rückert B, Jakiela B, Sanak M, Akdis M, Akdis CA.

J Allergy Clin Immunol. 2015 Nov;136(5):1413-6.e1-8. doi: 10.1016/j.jaci.2015.05.006. Epub 2015 Jun 19. No abstract available.

PMID:
26100085
10.

Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.

Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Res. 2015 May;3(5):495-505. doi: 10.1158/2326-6066.CIR-14-0165. Epub 2015 Jan 29.

11.

Phenotypic, ultra-structural, and functional characterization of bovine peripheral blood dendritic cell subsets.

Sei JJ, Ochoa AS, Bishop E, Barlow JW, Golde WT.

PLoS One. 2014 Oct 8;9(10):e109273. doi: 10.1371/journal.pone.0109273. eCollection 2014.

12.

Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.

Hodgson SH, Choudhary P, Elias SC, Milne KH, Rampling TW, Biswas S, Poulton ID, Miura K, Douglas AD, Alanine DG, Illingworth JJ, de Cassan SC, Zhu D, Nicosia A, Long CA, Moyle S, Berrie E, Lawrie AM, Wu Y, Ellis RD, Hill AV, Draper SJ.

Mol Ther. 2014 Dec;22(12):2142-54. doi: 10.1038/mt.2014.157. Epub 2014 Aug 26.

13.

Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).

Minang JT, Inglefield JR, Harris AM, Lathey JL, Alleva DG, Sweeney DL, Hopkins RJ, Lacy MJ, Bernton EW.

Vaccine. 2014 Nov 28;32(50):6847-54. doi: 10.1016/j.vaccine.2014.01.096. Epub 2014 Feb 13.

14.

Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells.

Wang J, Lau KY, Jung J, Ravindran P, Barrat FJ.

Eur J Immunol. 2014 Apr;44(4):1130-6. doi: 10.1002/eji.201344030. Epub 2014 Jan 20.

15.

Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.

Rijavec E, Genova C, Alama A, Barletta G, Sini C, Pronzato P, Coco S, Dal Bello MG, Savarino G, Truini A, Boccardo F, Grossi F.

Future Oncol. 2014 Jan;10(1):79-90. doi: 10.2217/fon.13.145. Review.

PMID:
24328411
16.

CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection.

Hu S, Chen H, Ma J, Chen Q, Deng H, Gong F, Huang H, Shi C.

J Appl Microbiol. 2013 Nov;115(5):1203-11. doi: 10.1111/jam.12315. Epub 2013 Aug 27.

17.

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.

Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ.

Cancer Biol Ther. 2013 Jul;14(7):557-63. doi: 10.4161/cbt.24598. Epub 2013 May 10.

18.

Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.

Hopkins RJ, Daczkowski NF, Kaptur PE, Muse D, Sheldon E, LaForce C, Sari S, Rudge TL, Bernton E.

Vaccine. 2013 Jun 26;31(30):3051-8. doi: 10.1016/j.vaccine.2013.04.063. Epub 2013 May 10.

19.

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.

Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB.

Br J Cancer. 2013 May 28;108(10):1998-2004. doi: 10.1038/bjc.2013.227. Epub 2013 May 7.

20.

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.

Winckelmann AA, Munk-Petersen LV, Rasmussen TA, Melchjorsen J, Hjelholt TJ, Montefiori D, Østergaard L, Søgaard OS, Tolstrup M.

PLoS One. 2013 Apr 26;8(4):e62074. doi: 10.1371/journal.pone.0062074. Print 2013.

Supplemental Content

Loading ...
Support Center